Story

111 Inc. Shares Rise on $4.52 per ADS Going-Private Proposal from Co-Founders

ENTHMSVIIDZHZH-TWJAKOHI
Sep 17, 20261 min read
111 Inc. Shares Rise on $4.52 per ADS Going-Private Proposal from Co-Founders

Summary

The China-based healthcare platform (NASDAQ: YI) saw its stock jump after receiving an unsolicited, non-binding offer from a buyer group including its founders to acquire the company and take it private.

Text size
Background

Shares of 111 Inc. (NASDAQ: YI) rose sharply in premarket trading Thursday after the company disclosed it received a non-binding proposal from its co-founders and an investment firm to take the company private.

The Buyout Offer

In a statement, the tech-enabled healthcare platform said its Board of Directors received the unsolicited offer on September 16, 2026. The buyer group includes company co-founders Dr. Gang Yu and Junling Liu, along with investment partner Huadeng Tech BioArray Ventures Ltd.

The proposal outlines an offer to acquire all outstanding Class A ordinary shares not currently owned by the consortium at a price of $4.52 per American Depositary Share (ADS) in cash. This is equivalent to $0.226 per Class A share, as each ADS represents twenty Class A shares. According to the filing, the buyers intend to fund the transaction with equity capital, including rollover equity and cash contributions.

Sample IUX Markets – In-articleAd

Market Reaction and Company Response

Investors reacted positively to the news, with 111 Inc.'s stock climbing 5.9% in premarket trading. The proposed price represents a premium over the stock's recent trading levels, which is typical in going-private transactions to incentivize shareholders.

The company's Board stated that it has just received the proposal and has not yet had an opportunity to evaluate its terms or decide on a response. 111 Inc. issued a standard cautionary note to its shareholders, stating that there is no assurance any definitive offer will be made, that an agreement will be executed, or that any transaction will be approved or consummated.

Read next

More on Stocks
Back to latest news

LATEST